Dr. T. Guaio, a Principal investigator (PI) at Great Eastern University (GEU), used a non-animal model to create a designer drug that pinpoints specific markers on the surface of cancer cells. Dr. Ty, a private practice veterinarian, and Guaio developed a plan to test the drug on privately owned dogs that visited Ty’s veterinary clinic. This was particularly exciting for Guaio because he lacked experience working with dogs and he had few fiscal resources to support the project. Guaio hoped to obtain preliminary data that could be used to supplement an NIH grant application for funding, and subsequently a New Drug Application (NDA).
Ty was interested in the collaboration because successful outcomes meant healthier animals, happier owners, and better business. As part of the collaboration, Ty provided tumor biopsy tissue to Guaio, who verified the presence of the tumor cell markers. Guaio then provided the designer drug to treat the dogs. In addition, Ty also provided clinical records such as scans and blood chemistry to validate the efficacy of the drug. Guaio used this information to analyze the efficacy of the treatment.
This is a preview of subscription content, access via your institution
